Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.
Bortezomib and the other licensed 20S proteasome inhibitors show robust activity against liquid tumors like multiple myeloma, but have disappointed against solid tumors including ovarian cancer. Consequently, interest is mounting in alternative non-peptide based drugs targeting the proteasome's...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a191fb5eadb24586b1e67b55b0cdb07d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a191fb5eadb24586b1e67b55b0cdb07d |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a191fb5eadb24586b1e67b55b0cdb07d2021-12-02T20:14:43ZChirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.1932-620310.1371/journal.pone.0256937https://doaj.org/article/a191fb5eadb24586b1e67b55b0cdb07d2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0256937https://doaj.org/toc/1932-6203Bortezomib and the other licensed 20S proteasome inhibitors show robust activity against liquid tumors like multiple myeloma, but have disappointed against solid tumors including ovarian cancer. Consequently, interest is mounting in alternative non-peptide based drugs targeting the proteasome's 19S regulatory particle subunit, including its ubiquitin receptor RPN13. RA183 and RA375 are more potent analogs of the prototypic inhibitor of RPN13 (iRPN13) called RA190, and they show promise for the treatment of ovarian cancer. Here we demonstrate that rendering these candidate RPN13 inhibitors chiral and asymmetric through the addition of a single methyl to the core piperidone moiety increases their potency against cancer cell lines, with the S-isomer being more active than the R-isomer. The enhanced cancer cell cytotoxicities of these compounds are associated with improved binding to RPN13 in cell lysates, ATP depletion by inhibition of glycolysis and mitochondrial electron chain transport, mitochondrial depolarization and perinuclear clustering, oxidative stress and glutathione depletion, and rapid accumulation of high molecular weight polyubiquitinated proteins with a consequent unresolved ubiquitin proteasome system (UPS) stress response. Cytotoxicity was associated with an early biomarker of apoptosis, increased surface annexin V binding. As for cisplatin, BRCA2 and ATM deficiency conferred increased sensitivity to these iRPN13s. Ubiquitination plays an important role in coordinating DNA damage repair and the iRPN13s may compromise this process by depletion of monomeric ubiquitin following its sequestration in high molecular weight polyubiquitinated protein aggregates. Indeed, a synergistic cytotoxic response was evident upon treatment of several ovarian cancer cell lines with either cisplatin or doxorubicin and our new candidate iRPN13s, suggesting that such a combination approach warrants further exploration for the treatment of ovarian cancer.Ravi K AnchooriLogan GeorgeSsu-Hsueh TsengBrandon LamSrinidhi PolkampallyAnjali D AmianoPalmer ForanHannah TsingineHarideep SamanapallyFernanda Carrizo VelasquezSamarjit DasDeyin XingAhmad Bin SalamBalasubramanyam KaranamChien-Fu HungRichard B S RodenPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 9, p e0256937 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Ravi K Anchoori Logan George Ssu-Hsueh Tseng Brandon Lam Srinidhi Polkampally Anjali D Amiano Palmer Foran Hannah Tsingine Harideep Samanapally Fernanda Carrizo Velasquez Samarjit Das Deyin Xing Ahmad Bin Salam Balasubramanyam Karanam Chien-Fu Hung Richard B S Roden Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors. |
| description |
Bortezomib and the other licensed 20S proteasome inhibitors show robust activity against liquid tumors like multiple myeloma, but have disappointed against solid tumors including ovarian cancer. Consequently, interest is mounting in alternative non-peptide based drugs targeting the proteasome's 19S regulatory particle subunit, including its ubiquitin receptor RPN13. RA183 and RA375 are more potent analogs of the prototypic inhibitor of RPN13 (iRPN13) called RA190, and they show promise for the treatment of ovarian cancer. Here we demonstrate that rendering these candidate RPN13 inhibitors chiral and asymmetric through the addition of a single methyl to the core piperidone moiety increases their potency against cancer cell lines, with the S-isomer being more active than the R-isomer. The enhanced cancer cell cytotoxicities of these compounds are associated with improved binding to RPN13 in cell lysates, ATP depletion by inhibition of glycolysis and mitochondrial electron chain transport, mitochondrial depolarization and perinuclear clustering, oxidative stress and glutathione depletion, and rapid accumulation of high molecular weight polyubiquitinated proteins with a consequent unresolved ubiquitin proteasome system (UPS) stress response. Cytotoxicity was associated with an early biomarker of apoptosis, increased surface annexin V binding. As for cisplatin, BRCA2 and ATM deficiency conferred increased sensitivity to these iRPN13s. Ubiquitination plays an important role in coordinating DNA damage repair and the iRPN13s may compromise this process by depletion of monomeric ubiquitin following its sequestration in high molecular weight polyubiquitinated protein aggregates. Indeed, a synergistic cytotoxic response was evident upon treatment of several ovarian cancer cell lines with either cisplatin or doxorubicin and our new candidate iRPN13s, suggesting that such a combination approach warrants further exploration for the treatment of ovarian cancer. |
| format |
article |
| author |
Ravi K Anchoori Logan George Ssu-Hsueh Tseng Brandon Lam Srinidhi Polkampally Anjali D Amiano Palmer Foran Hannah Tsingine Harideep Samanapally Fernanda Carrizo Velasquez Samarjit Das Deyin Xing Ahmad Bin Salam Balasubramanyam Karanam Chien-Fu Hung Richard B S Roden |
| author_facet |
Ravi K Anchoori Logan George Ssu-Hsueh Tseng Brandon Lam Srinidhi Polkampally Anjali D Amiano Palmer Foran Hannah Tsingine Harideep Samanapally Fernanda Carrizo Velasquez Samarjit Das Deyin Xing Ahmad Bin Salam Balasubramanyam Karanam Chien-Fu Hung Richard B S Roden |
| author_sort |
Ravi K Anchoori |
| title |
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors. |
| title_short |
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors. |
| title_full |
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors. |
| title_fullStr |
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors. |
| title_full_unstemmed |
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors. |
| title_sort |
chirality and asymmetry increase the potency of candidate adrm1/rpn13 inhibitors. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2021 |
| url |
https://doaj.org/article/a191fb5eadb24586b1e67b55b0cdb07d |
| work_keys_str_mv |
AT ravikanchoori chiralityandasymmetryincreasethepotencyofcandidateadrm1rpn13inhibitors AT logangeorge chiralityandasymmetryincreasethepotencyofcandidateadrm1rpn13inhibitors AT ssuhsuehtseng chiralityandasymmetryincreasethepotencyofcandidateadrm1rpn13inhibitors AT brandonlam chiralityandasymmetryincreasethepotencyofcandidateadrm1rpn13inhibitors AT srinidhipolkampally chiralityandasymmetryincreasethepotencyofcandidateadrm1rpn13inhibitors AT anjalidamiano chiralityandasymmetryincreasethepotencyofcandidateadrm1rpn13inhibitors AT palmerforan chiralityandasymmetryincreasethepotencyofcandidateadrm1rpn13inhibitors AT hannahtsingine chiralityandasymmetryincreasethepotencyofcandidateadrm1rpn13inhibitors AT harideepsamanapally chiralityandasymmetryincreasethepotencyofcandidateadrm1rpn13inhibitors AT fernandacarrizovelasquez chiralityandasymmetryincreasethepotencyofcandidateadrm1rpn13inhibitors AT samarjitdas chiralityandasymmetryincreasethepotencyofcandidateadrm1rpn13inhibitors AT deyinxing chiralityandasymmetryincreasethepotencyofcandidateadrm1rpn13inhibitors AT ahmadbinsalam chiralityandasymmetryincreasethepotencyofcandidateadrm1rpn13inhibitors AT balasubramanyamkaranam chiralityandasymmetryincreasethepotencyofcandidateadrm1rpn13inhibitors AT chienfuhung chiralityandasymmetryincreasethepotencyofcandidateadrm1rpn13inhibitors AT richardbsroden chiralityandasymmetryincreasethepotencyofcandidateadrm1rpn13inhibitors |
| _version_ |
1718374662974472192 |